Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/166001
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Roca i Ferrer, Jordi | - |
dc.contributor.author | Pujols Tarrés, Laura | - |
dc.contributor.author | Pérez-González, Maria | - |
dc.contributor.author | Alobid, Isam | - |
dc.contributor.author | Callejas, Francisco de Borja | - |
dc.contributor.author | Vicens Artés, Sònia | - |
dc.contributor.author | Fuentes Prado, Mireya | - |
dc.contributor.author | Valero, Antonio | - |
dc.contributor.author | Picado Vallés, César | - |
dc.contributor.author | Castor, Dennis | - |
dc.contributor.author | Nguyen, DucTung | - |
dc.contributor.author | Mullol i Miret, Joaquim | - |
dc.date.accessioned | 2020-06-17T10:32:50Z | - |
dc.date.available | 2020-06-17T10:32:50Z | - |
dc.date.issued | 2018-12-18 | - |
dc.identifier.issn | 1710-1492 | - |
dc.identifier.uri | http://hdl.handle.net/2445/166001 | - |
dc.description.abstract | Background: MP-AzeFlu, intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is superior to AZE or FP alone for treatment of allergic rhinitis (AR). However, the precise anti-inflammatory mechanism of action of MP-AzeFlu has not been characterized. Objective: To investigate the anti-inflammatory effects of MP-AzeFlu compared with AZE or FP alone in an established in vitro model of eosinophilic inflammation. Methods: Nasal mucosal epithelial cells and peripheral blood eosinophils were obtained from human volunteers. Epithelial cells were stimulated with 10% fetal bovine serum (FBS) in the presence of MP-AzeFlu, AZE, or FP (1:102 to 1:105 dilution). Concentrations of interleukin (IL)-6, IL-8, and granulocyte-macrophage colony-stimulating factor (GM-CSF) were measured by ELISA. Eosinophils were incubated in 10% human epithelial cell-conditioned medium (HECM) and survival assessed by trypan blue dye exclusion. Results are expressed as mean ± SEM percentage secretion/survival compared with FBS/HECM (respectively). Results: FP and MP-AzeFlu (all dilutions) and AZE (1:102) significantly reduced IL-6 secretion and eosinophil survival compared with positive controls. At 1:102 dilution, IL-6 secretion was significantly lower with MP-AzeFlu (38.3 ± 4.2%, compared with FBS = 100%) than with AZE (76.1 ± 4.9%) or FP (53.0 ± 4.9%). At 1:102 dilution, eosinophil survival was significantly lower with MP-AzeFlu at day 3 (17.5 ± 3.0%) and day 4 (2.4 ± 1.4%, compared with HECM = 100%) than with AZE (day 3: 75.2 ± 7.2%; day 4: 44.0 ± 9.7%) or FP (day 3: 38.5 ± 3.5%; day 4: 14.6 ± 4.0%). Conclusion: Greater reductions in cytokine secretion and eosinophil survival observed with MP-AzeFlu in vitro may underlie MP-AzeFlu's superior clinical efficacy vs. AZE or FP alone observed in AR patients. | ca |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | BioMed Central | ca |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s13223-018-0311-4 | - |
dc.relation.ispartof | Allergy, Asthma & Clinical Immunology, 2018, 14, 1, 86-NA | - |
dc.relation.uri | https://doi.org/10.1186/s13223-018-0311-4 | - |
dc.rights | cc-by (c) Roca i Ferrer et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Rinitis | - |
dc.subject.classification | Cèl·lules epitelials | - |
dc.subject.classification | Citoquines | - |
dc.subject.other | Rhinitis | - |
dc.subject.other | Epithelial cells | - |
dc.subject.other | Cytokines | - |
dc.title | Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-06-17T06:39:52Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca |
dc.identifier.idimarina | 4140263 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
12474_4140263_superior_effect_roca-ferrer_j_13223_2018_article_311.pdf | 990.03 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License